Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

RRM2 (ribonucleotide reductase M2)

Written2014-04Ali Afrasiabi, Hamid Fiuji, Reza Mirhafez, Amir Avan
Institute of Biochemistry, Biophysics (IBB), University of Tehran, Tehran, Iran (AAf); Department of ENT-Head, Neck Surgery, ENT-Head, Neck Surgery Research Center, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iran (AAf); Department of Biochemistry, Faculty of Science, Payame Noor University, Mashhad, Iran (HF); Department of New Sciences, Technology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran (RM); Department of Medical Oncology, VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands (HF, AAv)

Abstract Ribonucleotide reductase subunit M2 (RRM2) is located in chromosome-2 p25-p24, converts ribonucleotides to deoxynucleotides which is required for DNA polymerization and repair. It has been shown that RMM2 plays a key role in DNA synthesis, cell growth, and drug resistance of cancer cells. There is accumulating evidence that alteration in the expression level of RRM2 can have a substantial impact on the biological characteristics of cancer cells, including tumor initiation and progression, suggesting its role as a prognostic factor and a possible therapeutic target for cancer therapy. Therefore, this review highlights several recent and clinically relevant aspects of the expression and function of RRM2 in human cancer.

(Note : for Links provided by Atlas : click)

Identity

Alias_namesribonucleotide reductase M2 polypeptide
Other aliasR2
RR2
RR2M
HGNC (Hugo) RRM2
LocusID (NCBI) 6241
Atlas_Id 42175
Location 2p25.1  [Link to chromosome band 2p25]
Location_base_pair Starts at 10262863 and ends at 10271546 bp from pter ( according to hg19-Feb_2009)  [Mapping RRM2.png]
Local_order Based on MapViewer, gene flanking RRM2 oriented on 2p25-p24 are:
- KLF11 (Kruppel-like factor 11); 2p25,
- CYS1 (cystin 1); 2p25.1,
- RRM2 (ribonucleotide reductase M2); 2p25-p24,
- C2orf48 (chromosome 2 open reading frame 48); 2p25.1,
- MIR4261 (microRNA 4261); chromosome 2,
- HPCAL1 (hippocalcin-like 1); 2p25.1.
Fusion genes
(updated 2016)
ADD1 (4p16.3) / RRM2 (2p25.1)C2orf48 (2p25.1) / RRM2 (2p25.1)CDH3 (16q22.1) / RRM2 (2p25.1)
RRM2 (2p25.1) / C2orf48 (2p25.1)RRM2 (2p25.1) / NCKAP1 (2q32.1)RRM2 (2p25.1) / RREB1 (6p24.3)

DNA/RNA

 
  Table 1. Exons and introns of RRM2 gene. Figure 1. Ribonucleotide reductase subunit M2 (RRM2) is located in chr 2p25-p24. Synthesis of the encoded protein RRM2 is regulated in a cell-cycle dependent fashion and elevated to maximal levels during S-phase of cell cycle. RRM2 has two isoforms with different N-terminal lengths, variant 1 and 2, which contains 3452 and 3284 bp, respectively.
Description RRM2 gene has ten exons, nine introns and alternative promoters (Table 1). The alternative promoters are resulting in two isoforms with different N-terminal lengths (variants 1 and 2; Figure 1). Variants 1 and 2 contain 3452 and 3284 bp, respectively. Variant 1 is the longest isoform with respect to the variant 2.
Transcription Promoter of RRM2 gene has two transcription start sites, TATA box, three CCAAT boxes and several GC rich in 5' of the downstream transcription initiation site. Variant 2 has a shorter 5' UTR and uses a downstream translational start codon, compared to the variant 1. Regions of -204 to +1 and -659 to -257 act as a promoter for the variant 1 (1.65 kbp) and variant 2 (3.4 kbp), respectively. Several studies are currently ongoing for the role of the 3' UTR in the regulation of RRM2 expression. Moreover, three CCAAT boxes exist in the region between transcription initiating sites at positions -82, -109, -139 and -436. Also, the transcription of 1.65 kbp RRM2 mRNA initiates from +1, while 3.4 kbp mRNA RRM2 initiates at position -187 (Zhou and Yen, 2001).
Synthesis of the encoded protein (RRM2) is regulated in a cell-cycle dependent fashion and elevated to maximal levels during S-phase of cell cycle (Figure 1). RRM2 promoter has transcription factor binding sites for SP1, c-Ets, MZF1, E2F, Lyf-1, GATA-X, HSF2, AP-1, CdxA, IK-2, Sox-5, SRY, Brn-2, HNF-1, STATx, GATA-1, USF (c-Myc), Pbx-1, Oct-1, GATA-2, CRE-Bp and Nkx-2. 3.4 kbp RRM2 mRNA is the major form in kidney, placenta and lung, while 1.65 kbp RRM2 mRNA is the main form in small intestine, colon, testis and thymus. RRM2 gene expression level is high in small intestine, colon thymus and testis tissues. In addition RRM2 mRNA in heart is very higher with respect to other tissues. Conversely, the expression level of RRM2 gene is low in lung and liver tissues, and its level is very low level in prostate, skeletal muscle, brain and leukocyte tissues (Zhou and Yen, 2001; Park and Levine, 2000).
Pseudogene Related pseudogenes have been identified on chromosomes 1 and X (1p33→p31, 1q21→q23 and Xp21→p11).

Protein

Description The building blocks of DNA, deoxyribonucleotide triphosphates (dNTPs), is provided/generated by ribonucleotide reductases (RNR). In fact RNR have a vital role in preserving the appropriate amount of dNTPs (dATP, dGTP, dCTP, dTTP) pool for DNA replication and repair by converting ribonucleotide diphosphates (NDP) to deoxyribonucleotide diphosphates (dNDP). RNR enzymes are divided into three different classes: I, II and III. Human RNR belongs to the class I. Furthermore, RNR has two subunits, RRM1 and RRM2. RRM1 is the larger subunit of RNR with respect to the RRM2. RRM2 isoform 1 and 2 have 449 and 389 residues, respectively. In particular, isoform 1 has 60 residues more than isoform 2 inits N-terminal region. RRM2 interact with RRM1 through its C-terminus region (Nordlund and Reichard, 2006; Eklund et al., 2001; Thelander, 2007).
Expression RRM2 protein expression is increased to maximal level during S-phase due to E2F, as an activator of DNA synthesizing enzymes, however, its exression is reduced during G1 by E2F4 (Eklund et al., 2001; Nordlund and Reichard, 2006).
Function RRM2 contains a KEN-box on the N-terminus that is recognized during the mitosis by the Cdh1-anaphase-promoting complex and thereby becomes poly-ubiquitinated or depredates by proteasome (Nordlund and Reichard, 2006; Eklund et al., 2001; Thelander, 2007). RRM2 is responsible for producing a stable tyrosyl radical for the active site of RNR that is located in RRM1. In addition, p53R2 is 80% similar to RRM2, which can bind to RRM1 and form the active structure. According to the vital role of RNR in cell cycle and proliferation, RNRs can be considered as suitable targets for cancer treatment. Several studies have been demonstrated that inhibition of RRM2 can inhibit cancer cell growth and overcomes drug resistance (Aimiuwu et al., 2012; Zhou et al., 2013). In particular, Zhou and colleagues showed that inhibition of RRM2 by novel RNR inhibitor COH29 inhibited the proliferation of most cell lines in the human cancer panel, mostly ovarian cancer and leukemia. In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth with respect to the control group (Zhou et al., 2013).
Homology The RRM2 gene is conserved in Rhesus monkey, dog, chicken, cow, mouse, rat, K. lactis, fruit fly, mosquito, C. elegans, M. oryzae, S. cerevisiae, S. pombe, E. gossypii, N. crassa, and A. thaliana. Percentage of identity or homology of RRM2 in DNA and protein levels in eukaryots with respect to human is shown in Table 2.
 

Mutations

Note More than 1215 single nucleotide variations (SNPs) have been reported in RRM2 gene (until 5th of March 2014, dbSNP), such as rs15516, rs1130609, rs1138727, rs1138728, rs1138729, rs4668664, etc.

Implicated in

Note
  
Entity Pancreatic cancer
Note Youns and colleagues recently showed that RRM2 is overexpressed in the pancreatic cancer cell lines. They performed a gene expression profiling to identify novel molecular targets modulating the growth inhibitory effects of COX-2 inhibitor NS-398 in pancreatic cancer. They found that RRM2 was down-regulated in BxPC-3, MiaPaCa-2 and ASPC-1 cell lines after treatment with NS-398. Moreover, they identified RRM2 as a biomarker for the chemo-preventive effect of NS-398 in pancreatic cancer cells (Youns et al., 2011). Previous study illustrated that over-expression of RRM2 was associated with resistance to gemcitabine in pancreatic cancer (Nakano et al., 2007). In this study the expression level of RRM2 was analysed by q-PCR in different subclones during the development of acquired resistance to gemcitabine. This analysis showed that the expression level of RRM2 enhanced during the development of gemcitabine resistance. Moreover, they also evaluated the expression levels of other genes, RRM1, dCK, hENT1. This results illustrated that expression ratio significantly correlated with gemcitabine sensitivity in eight pancreatic cancer cell lines, whereas no single gene expression level correlated with the sensitivity, indicating that the sensitivity of pancreatic cancer cells to gemcitabine is dependent on the ratio of four factors involved in gemcitabine transport and metabolism. On the one hand, the ratio of the four gene expression associated with acquired gemcitabine-resistance in pancreatic cancer cells (Nakano et al., 2007). Moreover, Duxbury et al., showed that small interfering RNA targeting RRM2 enhanced chemosensitivity to gemcitabine in pancreatic adenocarcinoma (Duxbury et al., 2004), suggesting its role as an attractive target for pancreatic cancer.
  
  
Entity Lung cancer
Note Several studies have been shown that RRM2 is overexpressed in lung cancer. In particular, Souglakos and colleagues showed that patients with low level of RRM2 had a significantly higher response rate (60% vs 14.2%), time to progression (9.9 vs 2.3 months), and overall survival (15.4 vs 3.6 months) in metastatic lung adenocarcinoma patients treated with gemcitabine plus docetaxel with respect to the patients with high level of RRM2 (Souglakos et al., 2008). Furthermore, Boukovinas et al., evaluated the effect of RRM2 expression on outcome to gemcitabine plus docetaxel in advanced non-small-cell lung cancer (NSCLC) patients. RRM1, RRM2 and BRCA1 mRNA levels were determined by quantitative PCR and correlated with response, time to progression and survival. This study showed that the probability of response decreased (RRM2: Odds Ratio, 0.94; p<0.0001) and the risk of progression increased (RRM2: HR, 1.005; p = 0.01) in patients samples with high expression of RRM2, compared to the samples with low expression (Boukovinas et al., 2008). In another recent study the prognostic value of RRM2 was determined in 418 patients with NSCLC who received adjuvant chemotherapy (Wang et al., 2014). This analysis demonstrated that patients with low expression of RRM2 had a significantly higher responce to platinum-based chemotherapy (OR = 1.64, 95 % CI = 1.09-2.48) and a longer time to progression and overall survival time, with hazard ratio of 0.57 (0.38-0.86) and 0.47 (0.31-0.71), respectively (Wang et al., 2014).
  
  
Entity Breast cancer
Note It has been shown that RRM2 is overexpressed in human breast carcinoma tissue (DCIS, Jensen et al., 1994). Recently Kretschmer and colleagues identified molecular markers for the ductal carcinoma in situ using WAP-TNP8 mouse model. In particular, they identified seven marker genes (RRM2, MUC1, SPP1, FOXM1, EXO1, NUSAP1 and DEPDC1), which were overexpressed at a very early stage of premalignancy and preneoplasia of breast carcinomas (Kretschmer et al., 2011).
  
  
Entity Ovarian cancer
Note Ferrandina and colleagues found a association between RRM2 expression level and relative risk of death in ovarian cancer. In this study they evaluated the mRNA expression levels of several genes involved in transportation and metabolism of gemcitabine, including RRM2, in 25 primary ovarian carcinomas using q-PCR. They showed that samples with high RRM2 expression had a less overall survival, OS, (median OS=19 months) with respect to the samples with low RRM2 level (median OS=36 months; Ferrandina et al., 2010).
  
  
Entity Osteosarcoma
Note Fellenberg et al., in 2007 investigated the prognostic value of eight genes including RRM2 in 35 formalin-fixed osteosarcoma biopsies. They observed a significant relation between RRM2 expression with overall survival of the patients. However, the prognostic value of this gene did not confirm by multivariate analysis and further studies are needed to evaluate the prognostic role of RRM2 in osteosarcoma (Fellenberg et al., 2007).
  
  
Entity Bladder cancer
Note Lu and colleagues investigated whether global gene expression profiling can help in predecting the suitability of rodent models of bladder cancer for the detection of cancer-related genes and prediction of cancer prevention in human bladder cancer and carcinogen-induced rodent models. They found that 13~34% of whole genome were differentially expressed between tumor and normal tissues in humans, Fischer-344 rats, and B6D2F1 mice. Approximately 20% of these differentially expressed genes overlapped among species, corresponding to 2.6 to 4.8% of whole genes in the genome. A number of genes were consistently dysregulated in bladder tumors in both humans and rodents. Among these genes, RRM2 was up-regulated in tumor tissue across three species, suggesting its role as a potential factor in contributing to bladder carcinogenesis (Lu et al., 2010).
  
  
Entity Hepatocellular carcinoma
Disease Patients with hepatocellular carcinoma (HCC) suffer from chronic hepatitis or liver cirrhosis. Satow and colleagues performed whole-genome RNA interference-based functional screening in order to identify genes that sensitize lung cancer cells to drug and genes required for proliferation and survival of HCC cells. In this study four genes (AKR1B10, HCAP-G, RRM2, and TPX2) were found to be expressed strongly in HCC, suggeting their role as potential therapeutic targets in hepatocellular carcinoma (Satow et al., 2010).
  
  
Entity Gastric cancer
Note Morikawa et al., in 2010, explored the prognostic value of RRM2 in 112 gastric cancer samples using immunohistochemistry (Morikawa et al., 2010). They found that RRM2 expression was limited to the neck regions of gastric pits, in normal gastric mucosa. Moreover, they observed RRM2 overexpression in 72 cases (64.3%), among 112 gastric cancer tissues. In vitro analysis and inhibition of RRM2 systhesis by small interfering RNA, inhibited the growth of three gastric cancer cell lines, MKN-1, MKN-7, and SNU-719. Furthermore, they demonstarted that overexpression of RRM2 was associated with the gastric cancer progression and suppression of its function could be considered as a potential therapeutic strategy in gastric cancer (Morikawa et al., 2010).
  
  
Entity Parkinson disease
Note The inhibitory effect of dopamine on RRM1/2 has been reported in Parkinson disease. Dopamine inhibits RNR through two pathways: (I) dopamine acts as an effective radical scavenger and scavenge the tyrosyl radical of RRM2, which is important for initiating of catalytic process in RRM1 active site and (II) chelates the iron center of RRM2 which acts as a chelator for iron and other metals. In addition nitric oxide induces dopaminergic neuronal cells through inhibiting RNR (Woldman et al,. 2005; Ebadi and Sharma, 2003).
  

To be noted

This study was supported by grants from CCA Foundation 2012 (Amir Avan), Iranian grant from Department of New Sciences and Technology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran (Amir Avan).

Bibliography

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci G, Chan KK.
Blood. 2012 May 31;119(22):5229-38. doi: 10.1182/blood-2011-11-382226. Epub 2012 Apr 19.
PMID 22517893
 
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD, Hung SW, Krentz M, Patel D, Lovin D, Manoharan R, Thomson JM, Govindarajan R.
PLoS One. 2013;8(1):e53436. doi: 10.1371/journal.pone.0053436. Epub 2013 Jan 15.
PMID 23335963
 
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J.
PLoS One. 2008;3(11):e3695. doi: 10.1371/journal.pone.0003695. Epub 2008 Nov 11.
PMID 19002265
 
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE.
Surgery. 2004 Aug;136(2):261-9.
PMID 15300189
 
Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Ebadi M, Sharma SK.
Antioxid Redox Signal. 2003 Jun;5(3):319-35. (REVIEW)
PMID 12880486
 
Structure and function of the radical enzyme ribonucleotide reductase.
Eklund H, Uhlin U, Farnegardh M, Logan DT, Nordlund P.
Prog Biophys Mol Biol. 2001 Nov;77(3):177-268. (REVIEW)
PMID 11796141
 
Immunocytochemical evidence for the cytoplasmic localization and differential expression during the cell cycle of the M1 and M2 subunits of mammalian ribonucleotide reductase.
Engstrom Y, Rozell B.
EMBO J. 1988 Jun;7(6):1615-20.
PMID 3049070
 
Prognostic significance of drug-regulated genes in high-grade osteosarcoma.
Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A.
Mod Pathol. 2007 Oct;20(10):1085-94. Epub 2007 Jul 27.
PMID 17660802
 
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.
Cancer Chemother Pharmacol. 2010 Mar;65(4):679-86. doi: 10.1007/s00280-009-1073-y. Epub 2009 Jul 29.
PMID 19639316
 
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.
Goan YG, Zhou B, Hu E, Mi S, Yen Y.
Cancer Res. 1999 Sep 1;59(17):4204-7.
PMID 10485455
 
Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
Jensen RA, Page DL, Holt JT.
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9257-61.
PMID 7937751
 
Identification of early molecular markers for breast cancer.
Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W.
Mol Cancer. 2011 Feb 11;10(1):15. doi: 10.1186/1476-4598-10-15.
PMID 21314937
 
Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.
Lu Y, Liu P, Wen W, Grubbs CJ, Townsend RR, Malone JP, Lubet RA, You M.
Am J Transl Res. 2010 Sep 20;3(1):8-27.
PMID 21139803
 
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M.
Hum Pathol. 2010 Dec;41(12):1742-8. doi: 10.1016/j.humpath.2010.06.001. Epub 2010 Sep 9.
PMID 20825972
 
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
Br J Cancer. 2007 Feb 12;96(3):457-63. Epub 2007 Jan 16.
PMID 17224927
 
Ribonucleotide reductases.
Nordlund P, Reichard P.
Annu Rev Biochem. 2006;75:681-706. (REVIEW)
PMID 16756507
 
Characterization of the promoter of the human ribonucleotide reductase R2 gene.
Park JB, Levine M.
Biochem Biophys Res Commun. 2000 Jan 19;267(2):651-7.
PMID 10631117
 
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T.
Clin Cancer Res. 2010 May 1;16(9):2518-28. doi: 10.1158/1078-0432.CCR-09-2214. Epub 2010 Apr 13.
PMID 20388846
 
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R.
Br J Cancer. 2008 May 20;98(10):1710-5. doi: 10.1038/sj.bjc.6604344. Epub 2008 Apr 15.
PMID 18414411
 
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y.
Nature. 2000 Mar 2;404(6773):42-9.
PMID 10716435
 
Ribonucleotide reductase and mitochondrial DNA synthesis.
Thelander L.
Nat Genet. 2007 Jun;39(6):703-4.
PMID 17534360
 
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Wang L, Meng L, Wang XW, Ma GY, Chen JH.
Tumour Biol. 2014 Mar;35(3):1899-906. doi: 10.1007/s13277-013-1255-4. Epub 2013 Oct 24.
PMID 24155212
 
Dopamine inhibits cell growth and cell cycle by blocking ribonucleotide reductase.
Woldman I, Reither H, Kattinger A, Hornykiewicz O, Pifl C.
Neuropharmacology. 2005 Mar;48(4):525-37. Epub 2005 Jan 25.
PMID 15755480
 
Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells.
Youns M, Efferth T, Hoheisel JD.
Eur J Pharmacol. 2011 Jan 10;650(1):170-7. doi: 10.1016/j.ejphar.2010.10.026. Epub 2010 Oct 20.
PMID 20969859
 
The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F, Yen Y.
Cancer Res. 2003 Oct 15;63(20):6583-94.
PMID 14583450
 
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, Gaur S, Smith DL, Yuan YC, Synold TW, Horne D, Yen Y.
Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26.
PMID 24072748
 
Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses.
Zhou B, Yen Y.
Cytogenet Cell Genet. 2001;95(1-2):52-9.
PMID 11978970
 

Citation

This paper should be referenced as such :
A Afrasiabi, F Fiuji, R Mirhafez, A Avan
RRM2 (ribonucleotide reductase M2)
Atlas Genet Cytogenet Oncol Haematol. 2015;19(1):32-37.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/RRM2ID42175ch2p25.html


Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
  t(3;5)(p21;q32) RBM6/CSF1R


External links

Nomenclature
HGNC (Hugo)RRM2   10452
Cards
AtlasRRM2ID42175ch2p25
Entrez_Gene (NCBI)RRM2  6241  ribonucleotide reductase regulatory subunit M2
AliasesR2; RR2; RR2M
GeneCards (Weizmann)RRM2
Ensembl hg19 (Hinxton)ENSG00000171848 [Gene_View]  chr2:10262863-10271546 [Contig_View]  RRM2 [Vega]
Ensembl hg38 (Hinxton)ENSG00000171848 [Gene_View]  chr2:10262863-10271546 [Contig_View]  RRM2 [Vega]
ICGC DataPortalENSG00000171848
TCGA cBioPortalRRM2
AceView (NCBI)RRM2
Genatlas (Paris)RRM2
WikiGenes6241
SOURCE (Princeton)RRM2
Genetics Home Reference (NIH)RRM2
Genomic and cartography
GoldenPath hg19 (UCSC)RRM2  -     chr2:10262863-10271546 +  2p25-p24   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)RRM2  -     2p25-p24   [Description]    (hg38-Dec_2013)
EnsemblRRM2 - 2p25-p24 [CytoView hg19]  RRM2 - 2p25-p24 [CytoView hg38]
Mapping of homologs : NCBIRRM2 [Mapview hg19]  RRM2 [Mapview hg38]
OMIM180390   
Gene and transcription
Genbank (Entrez)AK092671 AK123010 AK313719 BC001886 BC028932
RefSeq transcript (Entrez)NM_001034 NM_001165931
RefSeq genomic (Entrez)NC_000002 NC_018913 NT_005334 NW_004929298
Consensus coding sequences : CCDS (NCBI)RRM2
Cluster EST : UnigeneHs.226390 [ NCBI ]
CGAP (NCI)Hs.226390
Alternative Splicing GalleryENSG00000171848
Gene ExpressionRRM2 [ NCBI-GEO ]   RRM2 [ EBI - ARRAY_EXPRESS ]   RRM2 [ SEEK ]   RRM2 [ MEM ]
Gene Expression Viewer (FireBrowse)RRM2 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)6241
GTEX Portal (Tissue expression)RRM2
Protein : pattern, domain, 3D structure
UniProt/SwissProtP31350   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP31350  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP31350
Splice isoforms : SwissVarP31350
Catalytic activity : Enzyme1.17.4.1 [ Enzyme-Expasy ]   1.17.4.11.17.4.1 [ IntEnz-EBI ]   1.17.4.1 [ BRENDA ]   1.17.4.1 [ KEGG ]   
PhosPhoSitePlusP31350
Domaine pattern : Prosite (Expaxy)RIBORED_SMALL (PS00368)   
Domains : Interpro (EBI)Ferritin-like_SF    RNR-rel    RNR_small    RNR_small_AS   
Domain families : Pfam (Sanger)Ribonuc_red_sm (PF00268)   
Domain families : Pfam (NCBI)pfam00268   
Conserved Domain (NCBI)RRM2
DMDM Disease mutations6241
Blocks (Seattle)RRM2
PDB (SRS)2UW2    3OLJ    3VPM    3VPN    3VPO   
PDB (PDBSum)2UW2    3OLJ    3VPM    3VPN    3VPO   
PDB (IMB)2UW2    3OLJ    3VPM    3VPN    3VPO   
PDB (RSDB)2UW2    3OLJ    3VPM    3VPN    3VPO   
Structural Biology KnowledgeBase2UW2    3OLJ    3VPM    3VPN    3VPO   
SCOP (Structural Classification of Proteins)2UW2    3OLJ    3VPM    3VPN    3VPO   
CATH (Classification of proteins structures)2UW2    3OLJ    3VPM    3VPN    3VPO   
SuperfamilyP31350
Human Protein AtlasENSG00000171848
Peptide AtlasP31350
HPRD01587
IPIIPI00946732   IPI00945295   IPI00011118   IPI01014515   
Protein Interaction databases
DIP (DOE-UCLA)P31350
IntAct (EBI)P31350
FunCoupENSG00000171848
BioGRIDRRM2
STRING (EMBL)RRM2
ZODIACRRM2
Ontologies - Pathways
QuickGOP31350
Ontology : AmiGOG1/S transition of mitotic cell cycle  regulation of transcription involved in G1/S transition of mitotic cell cycle  ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor  ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor  ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor  protein binding  nucleus  nucleoplasm  cytoplasm  cytosol  cytosol  ribonucleoside-diphosphate reductase complex  DNA replication  deoxyribonucleoside diphosphate metabolic process  deoxyribonucleotide biosynthetic process  deoxyribonucleotide biosynthetic process  nucleobase-containing small molecule interconversion  metal ion binding  protein heterotetramerization  oxidation-reduction process  
Ontology : EGO-EBIG1/S transition of mitotic cell cycle  regulation of transcription involved in G1/S transition of mitotic cell cycle  ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor  ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor  ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor  protein binding  nucleus  nucleoplasm  cytoplasm  cytosol  cytosol  ribonucleoside-diphosphate reductase complex  DNA replication  deoxyribonucleoside diphosphate metabolic process  deoxyribonucleotide biosynthetic process  deoxyribonucleotide biosynthetic process  nucleobase-containing small molecule interconversion  metal ion binding  protein heterotetramerization  oxidation-reduction process  
Pathways : KEGGPurine metabolism    Pyrimidine metabolism    Glutathione metabolism    p53 signaling pathway   
REACTOMEP31350 [protein]
REACTOME Pathways113510 [pathway]   499943 [pathway]   69205 [pathway]   
NDEx NetworkRRM2
Atlas of Cancer Signalling NetworkRRM2
Wikipedia pathwaysRRM2
Orthology - Evolution
OrthoDB6241
GeneTree (enSembl)ENSG00000171848
Phylogenetic Trees/Animal Genes : TreeFamRRM2
HOVERGENP31350
HOGENOMP31350
Homologs : HomoloGeneRRM2
Homology/Alignments : Family Browser (UCSC)RRM2
Gene fusions - Rearrangements
Fusion : MitelmanC2orf48/RRM2 [2p25.1/2p25.1]  [t(2;2)(p25;p25)]  
Fusion : MitelmanRRM2/RREB1 [2p25.1/6p24.3]  [t(2;6)(p25;p24)]  
Fusion: TCGARRM2 2p25.1 RREB1 6p24.3 BRCA
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerRRM2 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)RRM2
dbVarRRM2
ClinVarRRM2
1000_GenomesRRM2 
Exome Variant ServerRRM2
ExAC (Exome Aggregation Consortium)RRM2 (select the gene name)
Genetic variants : HAPMAP6241
Genomic Variants (DGV)RRM2 [DGVbeta]
DECIPHER (Syndromes)2:10262863-10271546  ENSG00000171848
CONAN: Copy Number AnalysisRRM2 
Mutations
ICGC Data PortalRRM2 
TCGA Data PortalRRM2 
Broad Tumor PortalRRM2
OASIS PortalRRM2 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICRRM2  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDRRM2
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch RRM2
DgiDB (Drug Gene Interaction Database)RRM2
DoCM (Curated mutations)RRM2 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)RRM2 (select a term)
intoGenRRM2
NCG5 (London)RRM2
Cancer3DRRM2(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM180390   
Orphanet
MedgenRRM2
Genetic Testing Registry RRM2
NextProtP31350 [Medical]
TSGene6241
GENETestsRRM2
Huge Navigator RRM2 [HugePedia]
snp3D : Map Gene to Disease6241
BioCentury BCIQRRM2
ClinGenRRM2
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD6241
Chemical/Pharm GKB GenePA299
Clinical trialRRM2
Miscellaneous
canSAR (ICR)RRM2 (select the gene name)
Probes
Litterature
PubMed83 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineRRM2
EVEXRRM2
GoPubMedRRM2
iHOPRRM2
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Apr 12 11:39:03 CEST 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.